THE EXPERIENCE OF POLYENYLPHOSPHATIDYLCHOLINE TREATMENT OF THE PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Abstract
Conducted non-invasive assessment of index of liver fibrosis (IF) and clinical efficacy of polyenylphosphatidylcholine in the treatment of 30 patients NASH within 3-6 months. Monotherapy with this drug in a dose of 2 capsules 3 times a day resulted in a significant reduction of IF, indicators of cytolysis and cholestasis in 3 months. In 33.3% of cases there was a clear positive dynamics ultrasound picture of the liver. In 10 patients with insignificant dynamics of biochemical parameters the treatment was continued up to 6 months, after which liver function tests normalized. Treatment of patients with Nash polyenylphosphatidylcholine is effective, the treatment time should be between 3 to 6 months.
About the Authors
L. V. Maslovskii
Federal State Budgetary Institution of Additional Professional Education «Central State Medical Academy» Administrative Department of the President of the Russian Federation
Russian Federation
Russian Federation
I. V. Zverkov
Federal State Budgetary Institution of Additional Professional Education «Central State Medical Academy» Administrative Department of the President of the Russian Federation
Russian Federation
Russian Federation
O. N. Minushkin
Federal State Budgetary Institution of Additional Professional Education «Central State Medical Academy» Administrative Department of the President of the Russian Federation
Russian Federation
Russian Federation
References
1. Диагностика и лечение неалкогольной жировой болезни печени: метод. рекоменд. для врачей // под.ред В. Т. Ивашкина М.: МЕДпресс-информ,2012. 32 с.
2. Драпкина О. М., Ивашкин В. Т. // РЖГГК. 2014. Т. 24. № 4. С. 32-38.
3. Минушкин О.Н, Масловский Л. В. // Трудный пациент. 2004. № 3. с. 10-13.
4. Минушкин О. Н., Леонтьев С. И., Масловский Л. В., Зверков И. В. // Гепатология. 2005. № 1. с. 16-23
5. Минушкин О. Н., Леонтьев С. И., Масловский Л. В., Зверков И. В. // Тер.архив. 2007. № 1. с. 19-23
6. Brunt EM // Semin. Liver. Dis. 2001.21(1). р. 3-16.
7. Chalasani N, Younossi Z, Lavine JE et al. // Am. J. Gastroenterol. 2012. 107. р.811-26.
8. Gundermann K-J., Kuenker А., Kuntz Е., Drodzik М. // Pharmacological reports 2011. 63. р. 643-659
9. Harrison SA. Kadakia S. Lang KA. Schenker S. // Am. J. Gastroenterol. 2002. 97(11). р.2714-24.
10. Lazo M, Hernaez R, Eberhardt MS, et al. //Am J Epidemiol. 2013.178. р.38-45.
11. Lee JY, Kim KM, Lee SG et al. // J. Hepatol. 2007. 47(2). р.239-44.
12. Lieber CS. // Alcohol. Clin. Exp. Res. 1999. 23. р.944-949.
13. Ma X, Zhao J, Lieber CS // J Hepatol. 1996. 24. р.604-613.
14. Marchesini G., Bugianesi E., Forlani G. Et al. // Hepatology 2003. 37(4). р.917-23.
15. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. World Gastroenterology Organisation Global Guidelines, 2012, 29 Р.
16. Pagadala M, Zein CO, McCullough AJ. // Clin Liver Dis. 2009. 13. р.591-606
17. Poniachik J, Baraona E, Zhao J, Lieber CS // J Lab Clin Med. 1999. 133. р. 342-348.
18. Sanyal AJ., Campbell-Sargent C., Mirshahi F. et al. // Gastroenterology 2001 120(5). р.1183-92.
19. Vernon G, Baranova A, Younossi ZM. // Aliment Pharmacol Ther. 2011. 34. р.274-285.
20. Williams CD, Stenger J, Asike MI, et al. // Gastroenterology 2011.140. р.124-131.
21. Willner IR. Waters B. Patil SR. et al. // Am J Gastroenterol 2001. 96(10). р.2957-61.
Review
For citations:
Maslovskii L.V., Zverkov I.V., Minushkin O.N. THE EXPERIENCE OF POLYENYLPHOSPHATIDYLCHOLINE TREATMENT OF THE PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH). Experimental and Clinical Gastroenterology. 2016;(12):101-105. (In Russ.)
Views:
229
Email this article 